Anixa Biosciences Inc Cash Flow Statement
ANIX|12 years of annual SEC 10-K data (FY2011-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 12 fiscal years. All figures from audited SEC 10-K filings.
Anixa Biosciences Inc used $7M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$12.6M | -$13.6M | -$13.0M | -$11.6M | -$14.2M | -$5.0M | -$5.0M | -$1.4M | -$9.6M | -$10.1M | -$7.4M | -$5.2M |
| Depreciation & Amortization | - | - | $38.3K | $47.6K | $18.4K | $43.2K | $33.3K | $12.5K | - | - | $8.0K | $8.4K |
| Operating Cash Flow | -$7.3M | -$6.5M | -$4.9M | -$4.7M | -$4.3M | -$3.8M | -$3.4M | $1.4M | -$2.4M | -$3.2M | -$716.0K | -$2.4M |
| Capital Expenditures | - | - | $15.8K | $175.5K | $38.4K | $30.2K | $146.5K | $54.8K | $6.7K | - | $9.0K | $2.1K |
| Free Cash Flow | - | - | -$5.0M | -$4.9M | -$4.3M | -$3.8M | -$3.5M | $1.3M | -$2.4M | - | -$725.0K | -$2.4M |
| Share Buybacks | $6.0K | - | - | - | - | - | - | - | - | - | - | - |
| FCF Margin | - | - | -967.5% | -1966.8% | -387.6% | -1055.7% | -1176.1% | 14.1% | -65.1% | - | -72.3% | -329.5% |